Place your bets on “Blue Chip Biotech"


Andreas Burckhardt, Analyst WestLB

From a portfolio perspective, what a party we’ve had with the relative out-performance of European biotech companies versus the general equity markets in 2008, all the way up until early March this year! Although the industry also had a better run compared to its US peers (outperforming the AMEX and Nasdaq Biotechindex by 5% and 9% respectively in 2009), the situation has changed. It now seems the equity festivities have moved elsewhere. Since March, investors have been buying into the early signs of an economic recovery – that still lacks conclusive evidence – by switching into cyclical and financial stocks, and are shunning the biotechs. This in spite of the fact that on the scorecard, all the important indices (the DJ Stoxx, the S&P 500 and the Nasdaq) achieved stellar gains of 35% and more, while biotech performance in the EU and US stood at +15% on average.
Although the European biotech sector in general was not everyone’s darling in Q2/2009, we noticed a new stock-picking approach amongst investors. This was primarily seen in small cap stocks with a market-capitalisation of less than EUR50m – a designation that includes around half of the 132 listed firms in Europe. There some highly speculative buying activities in almost illiquid stocks caused hiccups of up to 250% returns, in many cases even without relevant news-flow. This happened especially in the UK and Norway, where performance lagged last year compared to the rest of Europe. Unfortunately, these investments did not mean institutional investors are back. Instead, the feeling is more like that at a roulette table. The gambling makes us uneasy, as two thirds of all small cap companies will face major funding problems within the next 12 months, and most don’t have a convincing survival plan. That said, it’s good to see that two-thirds of all listed European biotech firms have produced absolute returns so far in 2009, albeit at very low levels.
There is reason to question whether these are healthy signs of a new and sustainable trend. Cash is king, and it will remain so for both investors and companies. Unless we see a broader inflow of money into equities from asset managers or insurance companies regarded as generalists, life in the biotech sector will remain chancy. Due to the mixed picture in terms of product development (think prominent failures at Cytos or Santhera) and the absence of any takeovers in the large- and midsize area this year, the biotech sector is not yet attractive enough to initiate high-quality investment in the short-term, despite low valuations – one reason to expect the cry for government help from all over Europe to increase steadily in volume. Only in countries where local governments set up rescue funds are we likely to see strong rallies. In the meantime, we re­commend sticking to “Blue Chip Biotechs”, like Actelion, Qiagen or MorphoSys, which are undervalued and should benefit when stock markets go on the defensive again during the next market consolidation.



The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...



Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...



Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...



German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....



Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...



Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...


Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...



Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...



Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...



Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%


  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015

Current issue

All issues